Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EYP001a + peginterferon alfa-2a
- Development stage
- Phase 2
- Lead developer
- ENYO Pharma
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Oral, Subcutaneous
01
Overview
A fixed-dose combination therapy of **EYP001a (also known as vonafexor)**—an oral small molecule agonist of the farnesoid X receptor (FXR)—and **peginterferon alfa-2a**, developed for the treatment of chronic hepatitis B (CHB). EYP001a modulates bile acid, lipid, and glucose metabolism through FXR activation, leading to reduced hepatic inflammation and fibrosis. Peginterferon alfa-2a is a well-established antiviral agent acting as an immunomodulator that enhances antiviral immune responses. In clinical trials, the combination is being investigated for its ability to improve functional cure rates in virologically suppressed CHB patients by targeting both viral replication and host immune pathways.
- Other names
- vonafexor + peginterferon alfa-2a
02
Targets
FXR (Farnesoid x-activated receptor)IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on EYP001a + peginterferon alfa-2a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EYP001a + peginterferon alfa-2a.